In the last decade diadenosine polyphosphates (Ap n A) have emerged as a family of signalling dinucleotides involved in a great diversity of cellular functions [1, 2] . Although the biosynthesis of Ap n A appears to be rather non-specific, highly specific intracellular 
Ap n A cleaving enzymes, in addition to non-specific phosphodiesterases, are involved in Ap n A degradation [3, 4] . Diadenosine triphosphate hydrolase or Ap 3 Aase (EC 3.6.1.29) is an enzyme that specifically cleaves dinucleoside triphosphates; Ap 3 A is the preferred substrate, the products of its cleavage being AMP and ADP. This enzyme, a 30-35 kDa polypeptide in mammals, was first discovered in rat liver [5, 6] ; later the enzyme from various eukaryotic organisms was investigated [4] . In spite of those and other studies, the biological significance of the enzymatic cleavage of Ap 3 A and related dinucleotides has not been clarified. Ap 3 A appears to be involved in intracellular regulation of ATP-gated K + channels [7] , in interferon action [8] , and in the mechanisms of differentiation and apoptosis [9] . A series of recent findings has established that human Fhit protein, the product of the tumour suppressor gene FHIT, is a homodimeric enzyme of about 32 kDa displaying Ap 3 Aase activity [10] [11] [12] , and is able to suppress tumorigenicity in cancer cells lacking endogenous Fhit protein [13] . These results strongly suggest that Ap 3 A and/or related dinucleotides are involved in tumour suppression signalling, which has markedly renewed interest in Ap 3 A and Ap n A-interacting proteins. The similarity between the catalytic properties of the previously described non-human Ap 3 Aases and the Fhit protein [11, 14] suggests a close relationship among them, or even that they could be the same protein. However, the lack of data on a human Ap 3 Aase hinders its comparison with Fhit. In this communication we present a preliminary characterisation of partially purified human platelet Ap 3 Aase, and compare its properties with those of the Fhit protein.
Fluorogenic derivatives of Ap n A [15, 16] were used as enzyme substrates. To the best of our knowledge this is the first study reporting a characterisation of a diadenosine triphosphate hydrolase isolated from human material.
MATERIALS AND METHODS

Materials.
Concentrates of human platelets from healthy donors were obtained from the Servicio de Hematología, Hospital de La Candelaria (Santa Cruz de Tenerife). Human Fhit protein expressed in E. coli, a gift from Dr. C. Brenner, was obtained as described [17] . Fhit protein was at least 95% pure as checked by SDS/PAGE under reducing and non-reducing conditions; in both cases a major band corresponding to the 16.8 kDa monomer was observed. The fluorogenic substrates e-(Ap n A) n = 2-4 were prepared by chemical modification of Ap n A (Sigma, St. Louis, MO, U.S.A.) and their purity checked as described [18] . Crotalus durissus phosphodiesterase was from Boehringer (Manheim, Germany). Sephacryl S-100 HR, Sephacryl S-200 HR and DEAE-Sephacel were from Pharmacia Biotech. (Uppsala, Sweden). Suramin was from RBI (Natick, MA, U.S.A.). Molecular mass markers for gel filtration chromatography were from Sigma. Polyclonal anti-Fhit antibodies (ZR44 and ZP54 ) were from Zymed (San Francisko, CA, U.S.A.). All salts and acetonitrile HPLC grade were from Merck (Darmstadt, Germany). Enzyme purification. Concentrates of human platelets (700 ml) were processed to eliminate other contaminating blood cells and to fractionate platelet protein between 40% and 80% of ammonium sulphate saturation according to [19] . The protein pellet after 80% ammonium sulphate precipitation was redissolved in 50 mM Hepes KOH, pH 7.0, 0.1 M KCl, 5% glycerol (26 ml), divided into three aliquots and each subjected to gel-filtration chromatography on a Sephacryl S-200 column (26 mm´900 mm) equilibrated in the same buffer and eluted at 2.0 ml/min. Fractions of 6.0 ml were collected. The column was previously calibrated with Blue dextran, bovine serum albumin, carbonic anhydrase and cytochrome c. Fractions were assayed by non-continuous fluorimetric assays to localise those containing Ap 3 Aase and asymmetrical Ap 4 Aase activity. Fractions containing Ap 3 Aase and Ap 4 Aase were pooled (180 ml) and concentrated to 20 ml, the buffer being changed to 20 mM phosphate, pH 7.5, 10% glycerol, using an Amicon ultrafiltration cell with a 10 kDa cut-off membrane. Two 10 ml aliquots of the concentrated Sephacryl extract were applied onto a DEAE-Sephacel column (16 mm´150 mm) equilibrated with 20 mM phosphate, pH 7.5, 10% glycerol, and the column eluted at a flow rate of 0.5 ml/min with 75 ml of the same buffer, and then with a linear gradient of 200 ml 0-0.3 M KCl in the equilibrating buffer. The column was washed with 25 ml of 1.0 M KCl and re-equilibrated with the initial buffer. Fractions of 4.0 ml were collected and assayed for Ap 3 Aase and Ap 4 Aase activity using the non-continuous fluorimetric assay. Active fractions containing Ap 3 Aase and Ap 4 Aase were pooled separately, concentrated in 50 mM Hepes buffer, pH 7.0, 10% glycerol and stored in 250 ml aliquots at -40°C.
Enzymatic assays. Non-continuous fluorimetric assays were used to detect Ap 3 Aase, Ap 4 Aase and non-specific phosphodiesterase in the chromatographic eluates. Sample mixtures (300 ml) containing, 50 mM Hepes/ NaOH, pH 7.0, 4 mM MgCl 2 , 0.2 mg/ml BSA, protein extract (5-50 ml) and 2 mM substrate (e-(Ap 3 A), e-(Ap 4 A) or e-(Ap 2 A) to detect Ap 3 Aase, Ap 4 Aase or phosphodiesterase, respectively) were prepared in Eppendorf tubes and incubated at 37°C for 10-60 min. Reactions were stopped by cooling in an ice-water bath and fluorescence was immediately measured using a Hitachi F-2000 spectrofluorimeter (l ex 305 nm, l em 410 nm) to detect hydrolase activity.
Continuous fluorimetric assays for quantitative purposes were performed in quartz microcuvettes to record time-dependent fluorescence increase associated with e-(Ap 3 A) hydrolysis as previously detailed [14] . Assay mixtures (250 ml) contained 50 mM Hepes/ NaOH, pH 7.0, 4 mM MgCl 2 , 0.2 mg/ml BSA, the required concentration of substrate and enzyme (Ap 3 Aase or Fhit) and were incubated at 37°C under stirring for up to 5 min. To determine K m for e-(Ap 3 A), initial reaction rates were measured at fixed substrate concentrations ranging between 0.1 and 20 mM. Ap 3 Aase and Fhit protein concentrations were adjusted to obtain initial linear time-dependent fluorescence increases and total substrate consumption below 10%. HPLC assays using ion-pair conditions used to identify reaction products and quantify reaction rates were performed as previously detailed [14] .
Protein assays. Protein concentration was determined according to the Bradford method [20] using bovine serum albumin as standard.
RESULTS AND DISCUSSION
Protein extracts obtained by ammonium sulphate fractionation (40-80%) of platelet homogenates exhibit hydrolase activity on e-(Ap 3 A) and e-(Ap 4 A) due to Ap 3 Aase and asymmetrical Ap 4 Aase, respectively. The presence of asymmetrical Ap 4 Aase in human blood cells has previously been reported [19, 21] . Hydrolase activity on e-(Ap 2 A), the substrate used to detect non-specific phosphodiesterase activity, was negligible. The specific activity of Ap 3 Aase was 0.15 mU/mg. This is a low figure if compared to equivalent rat brain extracts with specific activities about 60 times higher (our own results, not shown and [4] ).
Gel-filtration chromatography of platelet extracts on Sephacryl S-200 demonstrates the presence of two well differentiated but partially overlapping peaks of Ap 3 Aase and Ap 4 Aase activities, eluting as expected for proteins of molecular sizes of about 30 and 20 kDa, respectively (Fig. 1A) . Fractions containing Ap 3 Aase and Ap 4 Aase were concentrated by ultrafiltration (Ap 3 Aase specific activity was 1.4 mU/mg at this stage) and subjected to ion-exchange chromatography on DEAE- (Fig. 1B) . Due to the scarcity of Ap 3 Aase obtained and to the repeatedly reported instability of Ap 3 Aases, further purification attempts, e.g. by affinity chromatography, were postponed and biochemical characterisation studies were performed with the enzyme obtained after the ion-exchange step. This preparation presents a specific activity of 34.0 mU/mg, with a purification factor of about 250 and 17% yield relative to the ammonium sulphate extract. Human platelet Ap 3 Aase exhibits hyperbolic kinetics ( Fig. 2A) [14] . Up to now the major differences between the Ap 3 Aase activity from human platelets and the Fhit enzyme were in their apparent molec- In gel-filtration chromatography, human Ap 3 Aase elutes as a well-shaped peak corresponding to a polypeptide of about 32 kDa (Fig. 3A) similarly to the previously studied rat and bovine Ap 3 Aases [4, 18] . SDS/PAGE indicates that this enzyme is a monomeric protein of about 30 kDa in mammals and 41 kDa in plants [23, 24] . Although it has been suggested that the Fhit protein functions in vivo as a homodimer of two 16.8 kDa monomers [11, 12] , the Fhit elution profile (Fig. 3A) suggests the presence of other larger enzymatically active forms in addition to the dimer. It is worth noting that soluble aggregates of the Fhit protein, larger than dimers, were detected by gel-filtration during purification of human Fhit protein expressed in E. coli [17] . Such observations suggest that after purification as a homodimer, the protein undergoes aggregation/dissociation. Polyclonal anti-Fhit antibodies differentially inhibit enzymatic activities of Fhit and platelet Ap 3 Aase. Indeed, as shown in Fig. 3B , the inhibitory effect of Fhit antibodies is stronger on Fhit than on platelet Ap 3 Aase. These results indicate that human platelet Ap 3 Aase and the Fhit protein are kinetically and immunochemically closely related enzymes, but they may differ in some structural aspects which deserve further investigation. We have also partially purified Ap 3 Aase activities from human leukocytes and placenta, initial data indicating that there are no significant differences in kinetic properties and molecular mass relative to the platelet Ap 3 Aase. The distinction between Fhit enzyme and other Ap 3 A-cleaving enzymes is a crucial point with basic and clinical implications. It has recently been demonstrated that human Fhit enzyme and lupin Ap 3 Aase (probably a plant homologue of human Ap 3 Aase) may be distinguished by using new selective inhibitors [25] . It follows from this fine observation that these inhibitors should now be tested to verify whether human Fhit enzyme and human Ap 3 Aase may be similarly distinguished. 
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